LONDON–(BUSINESS WIRE)–ApaTech has presented new clinical data for its unique synthetic bone graft, ActifuseTM, suggesting that it can provide a preferable alternative to the current ‘gold standard’ therapy, Iliac Crest Bone Graft (ICBG), in the treatment of patients with degenerative lumbar spine disease. ApaTech is a world leader in applying the science of silicon to bone graft technology.
Three new studies presented today at the North American Spine Society (NASS) Spring Break Meeting have shown that ActifuseTM has the potential to be as clinically effective as ICBG, without the problems associated with the latter.
The first study involved 38 patients with a diagnosis of lumbar stenosis, followed up two years after treatment with ActifuseTM as part of a standard lumbar fusion procedure. Fusion rates were graded at two years in excess of 81 percent. Results also showed a 68 percent decrease in pain experienced pre-operatively, as measured by the Visual Analogue Scale (VAS) (8.0 pre-operatively to 2.6 at two years), with 95 percent of patients reporting satisfaction levels that were good or excellent. There were no incidences of infection, bone graft complications or instrumentation failures.
